Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time (CanPREDDICT)
CanPREDDICT: Canadian Study of Prediction of Risk and Evolution to Dialysis, Death and Interim Cardiovascular Events Over Time
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Studientyp
Studientyp
Einschreibung (Tatsächlich)
Einschreibung
Kontakte und Standorte
Studienorte
-
-
Alberta
-
Calgary, Alberta, Kanada
- Foothills Hospital
-
Edmonton, Alberta, Kanada
- University of Alberta
-
-
British Columbia
-
Penticton, British Columbia, Kanada
- Penticton Regional Hospital
-
Vancouver, British Columbia, Kanada
- Vancouver General Hospital
-
Vancouver, British Columbia, Kanada
- BC Children's Hospital
-
Vancouver, British Columbia, Kanada
- St. Paul's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Kanada
- St. Boniface Hospital
-
-
Newfoundland and Labrador
-
St John's, Newfoundland and Labrador, Kanada
- Eastern Regional Health Authority, Health Sciences Centre
-
-
Nova Scotia
-
Halifax, Nova Scotia, Kanada
- QEII Health Sciences Centre
-
Sydney, Nova Scotia, Kanada
- Cape Breton District Health Authority
-
-
Ontario
-
Hamilton, Ontario, Kanada
- St Joseph's Hospital
-
Kingston, Ontario, Kanada
- Kingston General Hospital
-
London, Ontario, Kanada
- London Health Science Centre- Victoria Campus
-
London, Ontario, Kanada
- London Health Science Centre- University Campus
-
Oak Ridges, Ontario, Kanada
- York Central
-
Ottawa, Ontario, Kanada
- University of Ottawa
-
Timmins, Ontario, Kanada
- Timmins & District Hospital
-
Toronto, Ontario, Kanada
- St. Michael's Hospital
-
Toronto, Ontario, Kanada
- University Health Network
-
Toronto, Ontario, Kanada
- Sunnybrook Hospital
-
-
Quebec
-
Greenfield Park, Quebec, Kanada
- Charles Le Moyne Hospital
-
Montreal, Quebec, Kanada
- Royal Victoria Hospital
-
Montreal, Quebec, Kanada
- Hopital Du Sacre-Coeur
-
Montréal, Quebec, Kanada
- Maisonneuve-Rosemont Hopital
-
Quebec City, Quebec, Kanada
- CHUQ: L'Hôtel-Dieu de Québec
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
Beschreibung
Inclusion Criteria:
- Patients currently seen by a nephrologist, or referred for evaluation of CKD
- GFR between 15-45 ml/min
- Adults 19 years (depending on age of consent in province) or older
- At pediatric sites study participants will be eligible to participate at age 15 or older
Exclusion Criteria:
- Organ transplant recipient
- Life expectancy less than 12 months
- Acute Vasculitis
- Bioimpedance sub-study exclusion criteria:
- Amputation (readings are inaccurate)
- Any battery operated or electronic implanted device (such as pacemaker or implanted defibrillator - potential electrical hazard)
- Pregnant women
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
Anzahl der Gruppen / Kohorten
Kohorten und Interventionen
Gruppe / KohorteGruppe / Kohorte |
|---|
|
Bioimpedance sub-study cohort
Funded by a grant from Kidney Foundation of Canada, Dr. Catherine Clase initiated a bioimpedance sub-study across 7 centres and recruited n=416 within the CANPREDDICT population.
The study uses bioimpedance measurements to assess volume status to determine the multivariable relationship between baseline volume overload and subsequent cardiovascular events.
Subjects are followed at 6 months intervals for 2 years.
|
|
Ethnic enrichment cohort
Additional recruitment initiated and funded by the Principal Investigator, Adeera Levin for enriching the ethnic representation within the Canadian cohort on South Asian and Oriental Asian was completed from Sept 2012 to June 2013, n=53.
|
|
Original CanPreddict cohort
The original CanPreddict cohort was recruited from Jun 2008 - Oct 2009 has 2544 CKD patients across Canada.
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Renal Replacement Therapy
Zeitfenster: 6 monthly for 3 years, annually up to 5 years
|
Renal Replacement Therapy is defined as dialysis start or transplantation.
|
6 monthly for 3 years, annually up to 5 years
|
|
Cardiovascular events
Zeitfenster: 6 monthly for 3 years, annually up to 5 years
|
Cardiovascular events are defined as myocardial infarction, ischemic and hemorrhagic stroke, coronary revascularization, congestive heart failure, peripheral bypass and gangrenes, adjudicated by a nephrologist, cardiologist and neurologist.
|
6 monthly for 3 years, annually up to 5 years
|
|
Death
Zeitfenster: 6 monthly for 3 years, annually up to 5 years
|
Deaths are reported with source documentation and adjudicated for ischemic or congestive cardiovascular death, other cardiovascular death, non-cardiovascular death and unknown cause of death.
|
6 monthly for 3 years, annually up to 5 years
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Adeera Levin, University of British Columbia
Publikationen und hilfreiche Links
Allgemeine Veröffentlichungen
- Levin A, Rigatto C, Brendan B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O; CanPREDDICT investigators. Cohort profile: Canadian study of prediction of death, dialysis and interim cardiovascular events (CanPREDDICT). BMC Nephrol. 2013 Jun 11;14:121. doi: 10.1186/1471-2369-14-121.
- Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase C, Tang M, Djurdjev O. (2012). Canadian study of prediciont of death, dialysis and interim cardiovascular events: CanPREDDICT: Biomarkers improve prediction of one year outcomes in chronic kidney disease cohort. Clinical studies in CKD. Nephrology Dialysis Transplantation, 27(suppl 2), ii63-ii65.
- Levin A, Rigatto C, Barrett B, Madore F, Muirhead N, Holmes D, Clase CM, Tang M, Djurdjev O; CanPREDDICT Investigators. Biomarkers of inflammation, fibrosis, cardiac stretch and injury predict death but not renal replacement therapy at 1 year in a Canadian chronic kidney disease cohort. Nephrol Dial Transplant. 2014 May;29(5):1037-47. doi: 10.1093/ndt/gft479. Epub 2013 Dec 26.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Studienbeginn
Primärer Abschluss (Voraussichtlich)
Primärer Abschluss
Studienabschluss (Voraussichtlich)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- H07-02457
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .